pulmonx LUNG 深 沪
已收盘 10-31 16:00:00 美东时间
2.00
+0.240
+13.64%
华盛通- 最 高2.10
- 今 开1.76
- 成交量 210.99万股
- 最 低 1.74
- 昨 收 1.76
- 总市值 8149.32万
- 52周最高 9.37
- 市盈率 静 --
- 换手率 5.18%
- 52周最低 1.47
- 委 比 65.14%
- 总股本 4074.66万
- 历史最高 69.478
- 量 比 0.09
- 振 幅 20.45%
- 历史最低 1.47
- 每 手 1
- 风险率 2.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MIRXES-B（02629.HK）10月30日收盘跌1.6%，主力资金净流出544.95万港元
证券之星消息，截至2025年10月30日收盘，MIRXES-B(02629.HK)报收于64.5港元，下跌1.6%，成交量112.3万股，成交额7363.25万港元。
10-30 18:59
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
Pulmonx reports Q3 Preliminary results
Pulmonx press release (NASDAQ:LUNG): Q3 revenue expected to be approximately $21.5 million More on Pulmonx Pulmonx slumps as Piper Sandler downgrades despite Q2 beat Seeking Alpha’s Quant Rating on ...
10-29 17:31
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
Pulmonx Preliminary, Unaudited Q3 2025 Revenue Expected To Be ~$21.5M
Preliminary, Unaudited Third Quarter 2025 RevenueTotal worldwide revenue for the third quarter of 2025 is anticipated to be approximately $21.5 million.The Company plans to provide further details on its third quarter
10-28 04:22
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
Pulmonx Corporation announced the reappointment of Glen French as President and CEO, effective immediately, and the appointment of Derrick Sung as COO and CFO, effective November 3, 2025. Steve Williamson and Mehul Joshi have resigned from their roles to pursue other opportunities. Preliminary, unaudited third-quarter 2025 revenue is expected to be approximately $21.5 million. The company has rescheduled the release of its third-quarter financial...
10-27 20:05
销售额超可口可乐、麦当劳！全球超级零售商的自有品牌 如何成为“大牌”
先问个问题：你最多能说出几个自有品牌？ 胖东来的“DL”？盒马的“盒马工坊”？奥乐齐中国的“超值”？ 自有品牌已成为国内零售行业的“标配”。从传统商超到新零售玩...
10-24 10:17
Vol.322| 医疗器械及精准医疗产业与投资一周热点回顾
（来源：CHC医疗传媒） 针对关于放开诊所检验检测业务限制的全国人大代表建议，国家卫健委近日答复： 放宽诊所检验业务限制和促进小型化医疗设备在诊所普及。一是《诊...
10-10 14:31
Mirxes觅瑞获机构青睐 癌症早筛龙头市场预期向好
近日，建银国际证券有限公司发布研究报告，首次覆盖新加坡生物科技公司Mirxes Holding Limited（股票代号：02629.HK，下称“Mirxes觅瑞”），并给予“跑赢大市”评级，目标价100港元/股。
09-26 17:46
